Products
Lacidipine was commercially available in the form of film-coated tablets (Motens, off label). It was approved in many countries since 1992. Distribution was discontinued in 2016.
Structure and properties
Lacidipine (C26H33NO6, Mr = 455.5 g/mol) is a lipophilic dihydropyridine and structurally related to the precursor nifedipine.
Effects
Lacidipine (ATC C08CA09) is vasodilator and antihypertensive. The effects are due to blockade of calcium channels in vascular smooth muscle. It has a long half-life of up to 19 hours.
Indications
As monotherapy or in combination with other antihypertensive agents for the treatment of hypertension.
Dosage
According to the SmPC. The tablets are usually taken once daily in the morning at the same time of day. They should not be administered together with grapefruit juice.
Contraindications
Lacidipine is contraindicated in hypersensitivity, unstable angina, after recent myocardial infarction, and in severe aortic stenosis. For complete precautions, see the drug label.
Interactions
Lacidipine is metabolized by CYP3A4. Corresponding drug interactions with CYP inhibitors and inducers are possible. Other antihypertensive agents result in an increased reduction in blood pressure. Another interaction has been observed with ciclosporin.
Adverse effects
The most common possible adverse effects include weakness, edema, facial flushing, rash, itching, headache, drowsiness, palpable heartbeats, rapid heartbeat, frequent urination, indigestion, and nausea. Many of the side effects are a result of vasodilatation.
